‎Blocking the ‎CXCR3 receptor could reduce the recruitment of immunosuppressive cells or ‎attenuate the tumor-promoting effects of CXCL10, particularly in cancers where it ‎promotes metastasis and immune evasion.75 Therapies aimed at increasing CXCL10 expression in the tumor microenvironment have shown the potential to synergize with immune checkpoint inhibitors such as anti‐PD‐1 or anti‐CTLA‐4 therapies. The gene discussed is CTLA4; the disease is cancer.